Compass Therapeutics (CMPX) Return on Capital Employed (2019 - 2026)
Compass Therapeutics (CMPX) posted Return on Capital Employed of 37.2% for Q1 2026, down 7.98% sequentially from 34.45% in Q4 2025, and up 1389.0% YoY from 2.5% in Q1 2025.
Compass Therapeutics (CMPX) Return on Capital Employed (2019 - 2026) Analysis & Trends
Compass Therapeutics has reported Return on Capital Employed for 8 years, with the latest figure at 37.2% in Q1 2026.
- Quarterly Return on Capital Employed rose 1389.0% year-over-year to 37.2% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 37.2% (up 1389.0% YoY) and the FY2025 annual result came in at 43.87%, down 336.0% from the prior year.
- Return on Capital Employed declined to 37.2% in Q1 2026 per CMPX's latest filing, from 34.45% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 23.7% in Q1 2022 and troughed at 61.56% in Q2 2025.
- A 5-year average of 35.55% and a median of 34.44% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed surged 8836 bps in 2022, then slumped 2452 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 28.23% in 2022, then fell by 15 bps to 32.36% in 2023, then decreased by 29 bps to 41.67% in 2024, then advanced by 17 bps to 34.45% in 2025, then decreased by 8 bps to 37.2% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 37.2%, 34.45%, and 44.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | -44.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.66% |
| Mar 31, 2026 | -37.20% |
| Dec 31, 2025 | -34.45% |
| Sep 30, 2025 | -44.21% |
| Jun 30, 2025 | -61.56% |
| Mar 31, 2025 | -51.08% |
| Dec 31, 2024 | -41.67% |
| Sep 30, 2024 | -37.48% |
| Jun 30, 2024 | -37.04% |
| Mar 31, 2024 | -34.44% |
| Dec 31, 2023 | -32.36% |
| Sep 30, 2023 | -28.92% |
| Jun 30, 2023 | -27.91% |
| Mar 31, 2023 | -24.19% |
| Dec 31, 2022 | -28.23% |
| Sep 30, 2022 | -33.56% |
| Jun 30, 2022 | -26.43% |
| Mar 31, 2022 | -23.70% |
| Dec 31, 2021 | -55.03% |
| Mar 31, 2021 | -112.06% |